{"organizations": [], "uuid": "2e2daaccedabeb693f7b81b33d8604ec95eeaf3e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180110.html", "section_title": "Archive News &amp; Video for Wednesday, 10 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-shanghai-pharmaceuticals-holding-u/brief-shanghai-pharmaceuticals-holding-units-receive-gmp-certificate-idUSL4N1P51NH", "country": "US", "domain_rank": 408, "title": "BRIEF-Shanghai Pharmaceuticals Holding units receive GMP certificate", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-10T15:03:00.000+02:00", "replies_count": 0, "uuid": "2e2daaccedabeb693f7b81b33d8604ec95eeaf3e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-shanghai-pharmaceuticals-holding-u/brief-shanghai-pharmaceuticals-holding-units-receive-gmp-certificate-idUSL4N1P51NH", "ord_in_thread": 0, "title": "BRIEF-Shanghai Pharmaceuticals Holding units receive GMP certificate", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-shanghai pharmaceuticals holding", "sentiment": "negative"}, {"name": "gmp", "sentiment": "negative"}, {"name": "reuters) - shanghai pharmaceuticals holding co ltd", "sentiment": "neutral"}, {"name": "beijing headline news", "sentiment": "none"}, {"name": "jiangsu food and drug administration", "sentiment": "none"}, {"name": "shanghai food and drug administration", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 10 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd\n* Says Changzhou-based pharmaceuticals unit received goods manufacture practice (GMP) certificate from Jiangsu Food and Drug Administration, for its products including acyclovir, ganciclovir and production line\n* Says the valid period is until Dec. 25, 2022\n* Says Shanghai-based pharmaceuticals unit received goods manufacture practice (GMP) certificate from Shanghai Food and Drug Administration, for its products including flurbiprofen axetil\n* Says the valid period is until Dec. 26, 2022\nSource text in Chinese: goo.gl/15PQTv\nFurther company coverage: (Beijing Headline News)\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "https://goo.gl/15PQTv"], "published": "2018-01-10T15:03:00.000+02:00", "crawled": "2018-01-11T12:25:34.032+02:00", "highlightTitle": ""}